This article is more than 5 years old. Information may no longer be current.

VIDEO: Immunotherapy agent induces response in prostate cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — The use of sipuleucel-T in patients with hormone-sensitive and castration-resistant prostate cancer demonstrated an increase in the proliferation of CD4 and CD8 T cells at week 6 compared with baseline, according to results presented at the ASCO Annual Meeting.

Preliminary analyses demonstrated that patients who had a T-cell response had a longer overall survival, according to the researchers.

“The next step would be to try and do this in a prospective way in patients who are going on trial and to do it with bigger numbers so that [we] can make sure that it looks more like it’s not just a correlation, but this inducing of T cells is the causation of the patients living longer,”

Charles G. Drake, MD, PhD, director of genitourinary oncology and associate director for clinical research at the Herbert Irving Comprehensive Cancer Center, told HemOnc Today.

Reference:

Drake CG, et al. Abstract 5046. Presented at: ASCO Annual Meeting; June 2-6, 2017; Chicago.

Disclosure: Drake reports no relevant financial disclosures.